PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Epinephrine

Drugs in development · updated 30 October 2026

Epinephrine: clinical trials and development status

Other names and codes: Adrenaline, Neffy, Symjepi, Primatene Mist

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 22 August 2024

As of 30 October 2026 Epinephrine is in 24 active clinical trials (recruiting or ongoing, phases I–III) for 30 diseases. The most advanced phase is III.

24Active trials
IIIMost advanced phase
30Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Epinephrine and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Heart ArrestIII2NCT07442071
PainIII2NCT05964868
Child behaviorIII1NCT05839548
CholeraIII1NCT04750070
Dental pulp diseaseIII1NCT05839548
EpistaxisII–III1NCT06801522
HemorrhageII–III1NCT06456255
Myocardial infarction with ST segment elevationIII1NCT06847568
No reflow phenomenonIII1NCT06847568
Out-of-hospital cardiac arrestIII1NCT07442071
Paranasal sinus diseaseII–III1NCT06456255
Renal cell carcinomaIII1NCT07092566
Septic shockIII1NCT04750070
Severe acute malnutritionIII1NCT04750070
ShockIII1NCT04750070
Stomatognathic diseaseIII1NCT05839548
ThinnessIII1NCT04750070
AnaphylaxisII2NCT07891780
Hypersensitivity, ImmediateII2NCT07891780
Acute painII1NCT07068243
Chronic urticariaII1NCT06927999
Hairy cell leukemiaII1NCT01059786
Head and neck squamous cell carcinomaII1NCT07392580
NeoplasmII1NCT07785609
Postoperative hemorrhageII1NCT06057675
Postoperative painII1NCT07068243
Residual neoplasmII1NCT01059786
Wounds and InjuriesII1NCT06429501
HypersensitivityI1NCT07038746
ObesityEarly I1NCT06416969

Everything on Epinephrine

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch